Press

New health economic study proves the value of CADScor® in coronary disease diagnostics   Acarix PR CADScor HEOR publication SWE Acarix PR CADScor HEOR publication ENG            

Initial Dan-NICAD II results presented today at ESC   PR Acarix Dan-NICAD II abstract session SWE >> PR Acarix Dan-NICAD II abstract session ENG >>            

Preliminary Dan-NICAD II results to be presented at ESC   PM Acarix Dan-NICAD II SWE PM Acarix Dan-NICAD II ENG            

Acarix AB (publ) publishes Interim Report, January – June 2021     PR Acarix Q2 2021 eng >> PM Acarix Q2 2021 sv >> Acarix Q2 2021 eng >> Acarix Q2 2021 sv >>            

Acarix AB (publ) publishes Interim Report, January – March 2021     PM_Acarix_Interim Report_Q1 PM_Acarix_Rapport_Q1            

Announcement from Acarix's annual general meeting The annual general meeting 2021 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 2021 and the following resolutions were passed by the meeting. Due to the ongoing corona pandemic, ...

Acarix Publishes the Annual Report for 2020   Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release.   PM_Acarix_Year-End_2020 eng Acari...

Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to theannual general meeting to be held on Tuesday 11 May 2021. Acarix - Notice to AGM 2021 ENG(401266055.3) Acarix -...

Positive, long term prognostic data from the Dan-NICAD Istudy published in European Heart Journal- Digital Health Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 p...

Acarix AB (publ) publishes Year-End Report 2020A strong ending of an eventful year   The fourth quarter contributed strongly to our overall performance in 2020, with the market approvalfor CADScor® from the US Food and Drug Administration (FDA) as the ou...

Positive preliminary data from Acarix’s exploratory heart failure study SEISMO   Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application. Ac...

Acarix announces the last patient included in Dan-NICADII study   After the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of noninvasive diagnostic testing in patients with suspected Coronar...

FDA identifies exclusive code for the CADScor®System   After yesterday’s announcement and further analysis of the FDA approval,Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic ...

Acarix receives US market approval for the CADScor® System  Acarix AB (publ) today announced that the US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of the CADScor®System in the US.   PR_Acari...

Positive results from Acarix study presented at ISPOR, a leading health economics conference   Acarix AB (publ) today announced that the company’s real-life data analysis, made in co-operation with clinics in Germany and Austria, is published as a poster...

Correction: Interim report 2020-01-01 to 2020-09-30   In the interim report that Acarix submitted today, 12 November 2020, there is a minor error under theheading “Capitalization” (page 4 in the interim report) where the last sentence is to end with 2022...

Acarix changes Certified Advisor to Redeye   Acarix AB (publ) announces today that the company has entered into anagreement with Redeye AB regarding the position as Certified Adviser.Redeye AB will take over as Certified Adviser on October 19, 2020. Aca...

Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue   Acarix AB (”Acarix” or the "Company") has, as previously announced, completed the rights issue ofshares amounting to approximately SEK 56 mi...

Last day of trading in paid subscribed shares (Sw. BTA)   Last day of trading in subscribed paid shares ("BTA") in Acarix AB ("Acarix" or the “Company") willbe Thursday the 1 October 2020 and stop day will be Monday the 5 October 2020.In the rights issue...

Acarix announce final outcome in oversubscribed rights issue   Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of86,156,738 shares with preferential rights for the Company's existing shareholders, which wasresolved by...

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...

Acarix publishes a supplement to the prospectus The board of directors of Acarix AB ("Acarix" or the "Company") has prepared a supplement to theprospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarixwhich was ...

Acarix progresses with the German authorities Acarix AB (publ) today announced that the German Ministry of Health has stated that phonocardiography for ruling out coronary artery disease has potential for general use in Germany. The German Federal Joint C...

Acarix two largest shareholders transfer subscription rights free of charge –extends the subscription period   he shareholders Sunstone LSV Fund II K / S and SEED Capital DK II K / S have transferred allof the subscription rights they were entitled to in...

Acarix VD Per Persson presenterade på Redeye   Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarixsvd Per Persson hur han ser på bolaget och den pågåendeföreträdesemissionen. Han gav också en uppdatering kring bolagetsframsteg. Acar...

Acarix publishes prospectus in connectionwith rights issue of approximately SEK 56 million     Acarix_PR_publication_of_prospectus (1) Acarix_PM_offentliggörande_prospekt

Acarix AB (publ) publishes Interim Report, January – June 2020 For us and for many other companies, the pandemic and global uncertainty have caused delays in someprioritized projects. However, in combination with a dynamic capital market this has created ...

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...

The annual general meeting 2020 ("AGM") of Acarix AB  was held today on 14 May 2020 and the following resolutions were passed by the meeting...     Kommuniké_årsstämma_14_maj_2020_-_Acarix_(Eng) Kommuniké_årsstämma_14_maj_2020_-_Acarix_(Sve)

Acarix publishes Interim Report, January – March 2020 During the quarter we have kept focus on our priorities along with managing the impact from the globalCovid-19 situation...  PR_Acarix_Q1_2020 eng PM_Acarix_Q1_2020 sv

Last patient included in Acarix’s exploratory heart failure study, SEISMO Acarix AB (publ) today announced that the last patient has been included in the exploratory SEISMO study on a potential heart failure application. Acarix_PR_HF study 200511 ENG Ac...

Acarix publishes annual report for 2019   Malmö, April 23, 2020 Today, Thursday April 23, Acarix is publishing its Annual Report for 2019.. The Annual Report is also attached to this press release. PR_Acarix Annual Report 2019 Acarix Year-end report ...

Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to theannual general meeting to be held on Thursday 14 May 2020, at 10.00 at Baker & McKenzieAdvokatbyrå's premises...

Acarix AB (publ) today announced that the company has received feedbackfrom the German authorities, the Federal Joint Committee, G-BA, on its submission for reimbursement of the CADScor®System in Germany. Acarix_PR_GBA_ENG Acarix_PR_GBA_SVE    

Press release MAR | Successful rights issue enables increasedfocus on strategic initiatives   The fourth quarter of 2019 was eventful, and we had the opportunity to see progressin several areas. Importantly, we closed a rights issue of SEK 43 million, b...

Acarix AB (publ) today announced the initiation of the randomized, multicenter clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms suggestive of stable c...

Acarix AB (publ) (ACARIX: FN Stockholm) today announced the first commercial usage of the CADScor®System in the UK. Dr Amrit Takhar and his team at Wansford and Kingscliffe Practice, nearPeterborough, UK, is the first clinic in the UK to use the unique CAD...

Acarix AB (publ) (ACARIX: FN Stockholm) today announced the submission of a De Novo application to the American Food and Drug Administration (FDA) for the CADScor® System in preparation of a US market entry. The company is now cautiously initiating prepara...

Acarix finalized a rights issue to finance further market expansion

Press release MAR |Acarix announce final outcome in rights issue   Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of34,541,064 shares with preferential rights for the Company's existing shareholders, which wasresolv...

Trading in subscription rights and BTAs in Acarix' rights issue has been delayed, due to late submission of the application to Nasdaq. This situation is beyond Acarix control. Trading will commence tomorrow, October 10. All other information in the pres...

The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 16 August 2019, to carry out a new share issue of a maximum of 34,541,064 shares with pref...

The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 16 August 2019, to carry out a new share issue of a maximum of 34,541,064 shares with pref...

The board of directors of Acarix AB ("Acarix" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on 16 August 2019, resolved to carry out a new share issue of a maximum of 34,541,064 shares with preferential rig...

MAR | Announcement from Acarix's extra general meeting The extra general meeting ("EGM") of Acarix AB ("Acarix" or the "Company") was held today on 16 August 2019 and the following resolutions were passed by the meeting. Announcement from Acarix's extra ...

MAR | Interim Report January – June 2019   ”With CADScor®System we have a fantastic opportunity to revolutionize the way the healthcare system handles patients with suspected coronary artery disease, CAD. In our daily work at Acarix, we see that the need...

CADScor®System – Significantly more effective than current practice   Acarix AB (publ) (ACARIX: FN Stockholm) today announced the publication of a meta-analysis including 2245 patients showing Acarix’s leading CADScor®System is more than three times as e...

Notice of extra general meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the extra general meeting to be held on Friday 16 August 2019, at 10.00 at World Trade Center, Jungmansgatan 12 in Ma...

Acarix CADScor®System included in NICE guidelines (UK)   Acarix AB (publ) (ACARIX: FN Stockholm) today announced that the CADScor®System has been included as a first line investigation for ruling out suspected stable Coronary Artery Disease by the Britis...

Acarix participates on the Redeye Growth Day, Monday 10 June 2019 On Monday, June the 10th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic directions for Acarix. The Growth Day meeting will take place at Haym...

MAR | Announcement from Acarix’s annual general meeting May 2019   May 16, 2019 The annual general meeting (“AGM”) of Acarix AB (“Acarix” or the “Company”) was held today on 16 May 2019 and the following resolutions were passed by the meeting. Adoption...

MAR | Interim report, January – March 2019 May 16, 2019   ”After almost a year at Acarix, I am truly inspired by the opportunities our products offer to revolutionize heart diagnosis. We participate actively in congresses and scientific conferen...

MAR | Acarix publishes annual report for 2018   April 25, 2019 Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com. The Annual Report is found here. For further information, please contact:Per...

Notice of Annual General Meeting in Acarix AB   April 16, 2019 The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Thursday 16 May 2019, at 10.00 at Baker & McKenzie A...

Press release MAR | Market dynamics favourable for CADScor®System, addressing the challenges of the global healthcare market   ”After six months at Acarix, I clearly see our market evolving and a growing opportunity for our products aimed at revolut...

MAR | Submission of new dossier by the end of February 2019   Jan 15, 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursementdirectly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously,...

Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection Dec 17, 2018 Acarix has initiated a new explorative clinical study to develop a diagnostic algorithm possibly leading to a new functionality for early...

German Clinic Orders Second Acarix CADScor®System to Further Boost Patient Capacity Dec 10, 2018 After three months of strong results using Acarix’s CADScor®System to evaluate potential coronary artery disease, Dr Katarina Varga, who operates two clinics...

MAR | Interim Report, January – September 2018   Nov 14, 2018 ”During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospital´s clinical manag...

MAR | Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer Nov 13, 2018 Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has serv...

Acarix AB enters strategic alliance with MED Management to broaden the commercial platform toward the German outpatient market Oct 24, 2018 To increase awareness and knowledge of the unique rule-out technology offered by Acarix through its CADScor system...

Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users.   Acarix AB (publ) (“Acarix”), today reported positive feedback from German users of its handheld CADScor®System for ruling out C...

Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).   Sep 12, 2018 New customers orders CADScor®System for ruling out Coronary Artery Disease (CAD) Acarix AB (publ) (“Acarix”) rep...

Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program   3 sep, 2018 Acarix AB (publ) (“Acarix”), today reported positive feedback for the clinical stud...

Swedish hospitals successfully complete Acarix CADScor®System evaluations vs. current best clinical practice for ruling out Coronary Artery Disease 30 aug, 2018 Acarix AB (publ) (“Acarix”), today announced that two major Swedish hospitals – Kristianstad ...

Acarix Clinical Advisory Board confirms validity of its comprehensive clinical study program 30 aug, 2018 Acarix AB (publ) (“Acarix”), today reported positive feedback for the clinical study program in order to validate and expand the performance of the ...

Acarix presenting the CADScor®System at ESC in Munich: a revolutionary technology for early and rapid rule out of Coronary Artery Disease   Visit us at booth D500 Exhibition hall A2   Acarix AB’s (publ) (“Acarix”) ultra-sensitive acoustic CADScor®Syste...

MAR | Interim Report, January – June 2018   Acarix gains traction in key markets providing physicians and patients new opportunities ”Since the inception of Acarix, the company has been fully committed to developing a reliable, noninvasive and radiation-...

MAR | Interim, Januari – March 2018   CADScor®System launched in key markets   “Acarix introduced the CADScor®System on the German, Swedish and Danish markets 11 months ago, in June 2017. The introduction was made without general reimbursement, which is...

Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors Acarix, developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of a highly experienced marketing...

Acarix AB recruits Per Persson as Chief Commercial Officer   Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer. Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new ...

Notice of Annual General Meeting 2018 The shareholders of Acarix AB, reg. no. 559009-0667, (the ”Company”), are hereby convened to the annual general meeting to be held on Wednesday 23 May 2018, at 10.00 at Baker & McKenzie Advokatbyrå’s premises at V...

MAR | Annual report 2017   Today, Monday April 23, Acarix is publishing its Annual Report for 2017. For further information please contact:Christian Lindholm, Interim CEOE-mail: secli@acarix.comPhone: +46 705 118333 This information is information that...

MAR | Year-end Report January-December 2017   CADScor®System launched in key markets ”In 2017, we achieved historic milestones in Acarix – most noticeably the receipt of our first commercial order for CADScor®System in June and thus a confirmation of th...

Medtech specialist Acarix AB names Christian Lindholm as Interim CEO Acarix AB (publ) (“Acarix”), developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of the company’s current CFO, Christian Li...

DAN-NICADII study to expand the applicability of the non-invasive Acarix CADScor®System for rapid ruling out Coronary Artery Disease Jan 09, 2018 Handheld system rules out coronary arterial stenosis, saving valuable time in frontline triage and avo...